SRR1394713
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.486
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- COAGULATION+0.313
- ANGIOGENESIS+0.251
- MYOGENESIS+0.206
- PANCREAS_BETA_CELLS+0.205
- APICAL_SURFACE+0.179
- SPERMATOGENESIS+0.162
- ALLOGRAFT_REJECTION+0.159
- ESTROGEN_RESPONSE_LATE+0.117
Top 10 suppressed
- MYC_TARGETS_V1-0.641
- PROTEIN_SECRETION-0.582
- UNFOLDED_PROTEIN_RESPONSE-0.536
- MTORC1_SIGNALING-0.532
- DNA_REPAIR-0.519
- OXIDATIVE_PHOSPHORYLATION-0.491
- E2F_TARGETS-0.481
- MYC_TARGETS_V2-0.480
- ANDROGEN_RESPONSE-0.451
- G2M_CHECKPOINT-0.407
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1451964 | GTEX | — | 0.976 |
| 2 | SRR1316624 | GTEX | — | 0.973 |
| 3 | SRR1472079 | GTEX | — | 0.972 |
| 4 | SRR1339549 | GTEX | — | 0.971 |
| 5 | SRR1434138 | GTEX | — | 0.969 |
| 6 | SRR1474886 | GTEX | — | 0.968 |
| 7 | SRR1416096 | GTEX | — | 0.966 |
| 8 | SRR1348861 | GTEX | — | 0.964 |
| 9 | SRR1479759 | GTEX | — | 0.963 |
| 10 | SRR1375635 | GTEX | — | 0.963 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.486 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.313 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.251 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.206 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.205 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.179 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.162 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.159 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.117 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.109 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.102 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.083 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.069 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.046 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.033 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.029 | Inavolisib | — uncovered |